Found: 68
Select item for more details and to access through your institution.
Cardiac events in newly diagnosed acute myeloid leukaemia during treatment with venetoclax + hypomethylating agents.
- Published in:
- British Journal of Haematology, 2024, v. 204, n. 4, p. 1232, doi. 10.1111/bjh.19325
- By:
- Publication type:
- Article
Lung Injury Prediction Model in Bone Marrow Transplantation: A Multicenter Cohort Study.
- Published in:
- American Journal of Respiratory & Critical Care Medicine, 2024, v. 209, n. 5, p. 543, doi. 10.1164/rccm.202308-1524OC
- By:
- Publication type:
- Article
Venetoclax and hypomethylating agent combination therapy in newly diagnosed acute myeloid leukemia: Genotype signatures for response and survival among 301 consecutive patients.
- Published in:
- American Journal of Hematology, 2024, v. 99, n. 2, p. 193, doi. 10.1002/ajh.27138
- By:
- Publication type:
- Article
Venetoclax duration (14 vs. 21 vs. 28 days) in combination with hypomethylating agent in newly diagnosed acute myeloid leukemia: Comparative analysis of response, toxicity, and survival.
- Published in:
- American Journal of Hematology, 2024, v. 99, n. 2, p. E63, doi. 10.1002/ajh.27180
- By:
- Publication type:
- Article
Mast cell cytomorphology and treatment outcome in mast cell leukemia.
- Published in:
- American Journal of Hematology, 2024, v. 99, n. 1, p. E5, doi. 10.1002/ajh.27105
- By:
- Publication type:
- Article
Venetoclax plus hypomethylating agents in DDX41‐mutated acute myeloid leukaemia and myelodysplastic syndrome: Mayo Clinic series on 12 patients.
- Published in:
- British Journal of Haematology, 2024, v. 204, n. 1, p. 171, doi. 10.1111/bjh.19105
- By:
- Publication type:
- Article
Determinants of outcomes and advances in CD19‐directed chimeric antigen receptor therapy for B‐cell acute lymphoblastic leukemia.
- Published in:
- European Journal of Haematology, 2024, v. 112, n. 1, p. 51, doi. 10.1111/ejh.14132
- By:
- Publication type:
- Article
IDH1/2 inhibitor monotherapy in blast‐phase myeloproliferative neoplasms: A multicentre experience.
- Published in:
- British Journal of Haematology, 2023, v. 203, n. 3, p. e87, doi. 10.1111/bjh.19027
- By:
- Publication type:
- Article
Sodium‐glucose co‐transporter‐2 inhibitor therapy and unmasking of JAK2‐mutated myeloproliferative neoplasm: A Mayo Clinic series of nine consecutive cases.
- Published in:
- American Journal of Hematology, 2023, v. 98, n. 10, p. E276, doi. 10.1002/ajh.27034
- By:
- Publication type:
- Article
Sporadic and Familial Acute Myeloid Leukemia with CEBPA Mutations.
- Published in:
- Current Hematologic Malignancy Reports, 2023, v. 18, n. 5, p. 121, doi. 10.1007/s11899-023-00699-3
- By:
- Publication type:
- Article
U2AF1 pathogenic variants in myeloid neoplasms and precursor states: distribution of co-mutations and prognostic heterogeneity.
- Published in:
- Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00922-7
- By:
- Publication type:
- Article
Real-world experience with ponatinib therapy in chronic phase chronic myeloid leukemia: impact of depth of response on survival and prior exposure to nilotinib on arterial occlusive events.
- Published in:
- Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00891-x
- By:
- Publication type:
- Article
Blast phase myeloproliferative neoplasm: contemporary review and 2024 treatment algorithm.
- Published in:
- Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00878-8
- By:
- Publication type:
- Article
The clinical and molecular spectrum of ETV6 mutated myeloid neoplasms.
- Published in:
- British Journal of Haematology, 2023, v. 202, n. 2, p. 279, doi. 10.1111/bjh.18850
- By:
- Publication type:
- Article
Sodium‐glucose co‐transporter‐2 inhibitor use and JAK2 unmutated erythrocytosis in 100 consecutive cases.
- Published in:
- American Journal of Hematology, 2023, v. 98, n. 7, p. E165, doi. 10.1002/ajh.26933
- By:
- Publication type:
- Article
Spectrum of renal pathological findings in patients with chronic myelomonocytic leukemia and kidney injury.
- Published in:
- American Journal of Hematology, 2023, v. 98, n. 6, p. E148, doi. 10.1002/ajh.26902
- By:
- Publication type:
- Article
TP53 mutation variant allele frequency of ≥10% is associated with poor prognosis in therapy-related myeloid neoplasms.
- Published in:
- Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00821-x
- By:
- Publication type:
- Article
Observation and treatment in DDX41-mutated acute myeloid leukemia and myelodysplastic syndrome.
- Published in:
- Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00818-6
- By:
- Publication type:
- Article
Abnormal karyotype is an independent predictor of inferior survival in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN).
- Published in:
- Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00812-y
- By:
- Publication type:
- Article
A phase II study of combination d aunorubicin, cytarabine (A ra‐c), and nilotinib (TA signa) (DATA) in patients newly diagnosed with acute myeloid leukemia with KIT expression.
- Published in:
- American Journal of Hematology, 2023, v. 98, n. 3, p. 472, doi. 10.1002/ajh.26831
- By:
- Publication type:
- Article
Reduced intensity conditioning allogeneic hematopoietic stem cell transplantation in VEXAS syndrome: Data from a prospective series of patients.
- Published in:
- American Journal of Hematology, 2023, v. 98, n. 2, p. E28, doi. 10.1002/ajh.26786
- By:
- Publication type:
- Article
Co-mutational pattern of somatic GATA2-mutated myeloid neoplasms.
- Published in:
- Annals of Hematology, 2023, v. 102, n. 1, p. 211, doi. 10.1007/s00277-022-05016-1
- By:
- Publication type:
- Article
Abnormal karyotype is an independent predictor of inferior survival in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
- Published in:
- 2023
- By:
- Publication type:
- Letter
Pre-lymphodepletion & infusion endothelial activation and stress index as predictors of clinical outcomes in CAR-T therapy for B-cell lymphoma.
- Published in:
- Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-022-00777-4
- By:
- Publication type:
- Article
Observation and treatment in DDX41-mutated acute myeloid leukemia and myelodysplastic syndrome.
- Published in:
- 2023
- By:
- Publication type:
- Letter
CPX-351 (Vyxeos™) treatment in blast-phase myeloproliferative neoplasm (MPN-BP): real-world experience in 12 consecutive cases.
- Published in:
- Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00800-2
- By:
- Publication type:
- Article
TP53 mutation variant allele frequency of ≥10% is associated with poor prognosis in therapy-related myeloid neoplasms.
- Published in:
- Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00821-x
- By:
- Publication type:
- Article
Post-Transplant and In-Hospital Risk Factors for ARDS After Hematopoietic Stem Cell Transplantation.
- Published in:
- Respiratory Care, 2023, v. 68, n. 1, p. 77, doi. 10.4187/respcare.10224
- By:
- Publication type:
- Article
Autoimmune manifestations in STAG2-mutated myeloid neoplasms.
- Published in:
- Annals of Hematology, 2022, v. 101, n. 12, p. 2785, doi. 10.1007/s00277-022-04995-5
- By:
- Publication type:
- Article
Abnormal CD13/HLA-DR Expression Pattern on Myeloblasts Predicts Development of Myeloid Neoplasia in Patients With Clonal Cytopenia of Undetermined Significance.
- Published in:
- American Journal of Clinical Pathology, 2022, v. 158, n. 4, p. 530, doi. 10.1093/ajcp/aqac083
- By:
- Publication type:
- Article
Mast cell sarcoma: 2 Mayo Clinic cases.
- Published in:
- American Journal of Hematology, 2022, v. 97, n. 10, p. 1381, doi. 10.1002/ajh.26525
- By:
- Publication type:
- Article
Pilot Study Characterizing the Hematology-Oncology Fellow Job Search Process: Tools Used and Identification of Potential New Resources.
- Published in:
- Journal of Cancer Education, 2022, v. 37, n. 5, p. 1385, doi. 10.1007/s13187-021-01967-7
- By:
- Publication type:
- Article
A dynamic 3‐factor survival model for acute myeloid leukemia that accounts for response to induction chemotherapy.
- Published in:
- American Journal of Hematology, 2022, v. 97, n. 9, p. 1127, doi. 10.1002/ajh.26630
- By:
- Publication type:
- Article
Limited activity of fedratinib in myelofibrosis patients relapsed/refractory to ruxolitinib 20 mg twice daily or higher: A real‐world experience.
- Published in:
- British Journal of Haematology, 2022, v. 198, n. 4, p. e54, doi. 10.1111/bjh.18284
- By:
- Publication type:
- Article
Outcomes following venetoclax‐based treatment in therapy‐related myeloid neoplasms.
- Published in:
- American Journal of Hematology, 2022, v. 97, n. 8, p. 1013, doi. 10.1002/ajh.26589
- By:
- Publication type:
- Article
Therapy-related myeloid neoplasms following chimeric antigen receptor T-cell therapy for Non-Hodgkin Lymphoma.
- Published in:
- 2022
- By:
- Publication type:
- Letter
Real‐world experience with venetoclax and hypomethylating agents in myelodysplastic syndromes with excess blasts.
- Published in:
- American Journal of Hematology, 2022, v. 97, n. 6, p. E214, doi. 10.1002/ajh.26539
- By:
- Publication type:
- Article
Unique characteristics and outcomes of therapy-related acute lymphoblastic leukemia following treatment for multiple myeloma.
- Published in:
- Blood Cancer Journal, 2022, v. 12, n. 6, p. 1, doi. 10.1038/s41408-022-00680-y
- By:
- Publication type:
- Article
Acute seizures and status epilepticus in immune effector cell associated neurotoxicity syndrome (ICANS).
- Published in:
- 2022
- By:
- Publication type:
- Letter
Use of sublingual tacrolimus in adults undergoing hematopoietic cell transplant: A pilot study.
- Published in:
- Journal of Oncology Pharmacy Practice, 2022, v. 28, n. 2, p. 387, doi. 10.1177/1078155221995230
- By:
- Publication type:
- Article
Comparative study of therapy‐related and de novo adult b‐cell acute lymphoblastic leukaemia.
- Published in:
- British Journal of Haematology, 2022, v. 196, n. 4, p. 963, doi. 10.1111/bjh.17906
- By:
- Publication type:
- Article
Molecular markers demonstrate diagnostic and prognostic value in the evaluation of myelodysplastic syndromes in cytopenia patients.
- Published in:
- 2022
- By:
- Publication type:
- Letter
A novel Iowa–Mayo validated composite risk assessment tool for allogeneic stem cell transplantation survival outcome prediction.
- Published in:
- Blood Cancer Journal, 2021, v. 11, n. 11, p. 1, doi. 10.1038/s41408-021-00573-6
- By:
- Publication type:
- Article
Identification of adult Philadelphia-like acute lymphoblastic leukemia using a FISH‐based algorithm distinguishes prognostic groups and outcomes.
- Published in:
- 2021
- By:
- Publication type:
- Letter
Venetoclax with azacitidine or decitabine in blast‐phase myeloproliferative neoplasm: A multicenter series of 32 consecutive cases.
- Published in:
- American Journal of Hematology, 2021, v. 96, n. 7, p. 781, doi. 10.1002/ajh.26186
- By:
- Publication type:
- Article
Osteolytic lesions in myelofibrosis.
- Published in:
- Clinical Case Reports, 2021, v. 9, n. 7, p. 1, doi. 10.1002/ccr3.4276
- By:
- Publication type:
- Article
Pretransplant Risk Factors Can Predict Development of Acute Respiratory Distress Syndrome after Hematopoietic Stem Cell Transplantation.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Characteristics and Outcome of Periengraftment Respiratory Distress Syndrome after Autologous Hematopoietic Cell Transplant.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Clinical and biological characteristics and prognostic impact of somatic GATA2 mutations in myeloid malignancies: a single institution experience.
- Published in:
- 2021
- By:
- Publication type:
- Letter to the Editor
Immune-mediated neuromuscular complications of graft-versus-host disease.
- Published in:
- 2021
- By:
- Publication type:
- journal article